BioCardia outlines Japan Shonin filing in ~7 months and targets ~19-month path to approval for CardiAMP

Earnings Call Insights: BioCardia (BCDA) Q1 2026

MANAGEMENT VIEW

* "We have had significant accomplishments this last quarter for our CardiAMP Cell Therapy for the treatment of ischemic heart failure" (CEO, President & Director Peter Altman), highlighting FDA breakthrough designation and "Medicare reimbursement at $20,000 per treatment procedure today."
* "In our formal clinical consultation with Japan's Pharmaceutical and Medical Devices Agency, they have said that they are inclined to accept this data as the basis for regulatory submission and approval in Japan" (CEO, President & Director Altman), adding that BioCardia has already received "the draft written advisory record from the agency" and is preparing a Shonin submission.
* "We also completed a Q-Sub meeting with FDA Center for Biologics Evaluation and Research" (CEO, President & Director Altman), stating FDA "view the appropriate approval pathway as a premarket approval," "had no concerns on the safety," and "encouraged BioCardia to complete the ongoing CardiAMP HF II trial" while engaging on elements of statistical analysis.
* "For the second quarter of 2026, looking ahead, we expect to complete one or more transactions that will fund Japan PMDA submission for approval and the CardiAMP Heart Failure II trial" (CEO, President & Director Altman).
* "Total expense decreased by $460,000 quarter-over-quarter to $2.3 million" (Chief Financial Officer David McClung), and "the company ended the quarter with cash and cash equivalents totaling $951,000."

OUTLOOK

* BioCardia said it "expect[s]" the Japan Shonin application "will take approximately 7 months to prepare and submit" (CEO, President & Director Altman) and described a post-submission "about a year-long review process" (CEO, President & Director Altman).
* Management’s near-term priorities were framed as execution and financing, with the CEO stating: "Completing the CardiAMP Shonin premarket application for approval in Japan and enrolling CardiAMP Heart Failure II are our top priorities" (CEO, President & Director Altman).
* Compared with the prior quarter’s emphasis on upcoming catalysts and regulatory meetings, the company now characterized those regulatory interactions as completed outcomes, with the CEO saying: "We have delivered now on all 4 catalysts detailed on our last call, having 3 positive regulatory interactions" (CEO, President & Director Altman).

FINANCIAL RESULTS

* BioCardia reported "net loss was $2.3 million for the first quarter of 2026" and "net cash used in operations was $1.7 million" (Chief Financial Officer McClung).
* R&D spending was tied to shifting program activity: "research and development expense decreased $295,000 to $1.2 million" (Chief Financial Officer McClung), which he attributed primarily to "the closeout of the CardiAMP Heart Failure trial" partially offset by "early enrollment in the CardiAMP Heart Failure II trial and regulatory activities to advance CardiAMP in Japan."
* SG&A was described as lower on professional fees: "Selling, general and administrative expenses decreased to $1.0 million" (Chief Financial Officer McClung).

Q&A

* Laura Suriel, on behalf of Jim Molloy, Alliance Global Partners: asked for "more insight into the regulatory process in Japan" including needed work pre-submission and timing post-filing; CEO Altman said the process includes "auditing our clinical data" and "auditing our manufacturing" and reiterated, "we will complete the submission in roughly 7 months," followed by "about a year-long review process" with "a post-marketing study" and "reimbursement during that post-marketing study."
* Laura Suriel, on behalf of Jim Molloy, Alliance Global Partners: asked about Japan market opportunity and how CardiAMP integrates into treatment; CEO Altman said "there's roughly 300,000 patients in Japan with ischemic etiology heart failure" but initial use would be under "appropriate use conditions" and "we would expect it to be on the order of 20,000 patients," adding that using "the $20,000 reimbursement in the United States" implies "pretty quickly a $400 million market."

SENTIMENT ANALYSIS

* Analysts’ tone was neutral and detail-oriented, focusing on process, timing, and commercial scope (e.g., "what additional work" is needed and "what's the timing" for agency feedback) (Laura Suriel, on behalf of Jim Molloy, Alliance Global Partners).
* Management’s tone was positive and execution-focused around regulatory traction and planning, using confidence language such as "my expectation is it should go relatively straightforward" and "I don't expect any significant issues" (CEO, President & Director Altman), while tying next steps to funding: "we expect to complete one or more transactions" (CEO, President & Director Altman).
* Versus the previous quarter, management sentiment shifted from anticipatory (multiple near-term catalysts described as pending) to outcome-based and milestone-driven (regulatory interactions described as completed and "positive") (CEO, President & Director Altman).

QUARTER-OVER-QUARTER COMPARISON

* Regulatory narrative moved from planning to reported outcomes: in Q4 2025 BioCardia said it "expect[ed]" an FDA Q-sub discussion and a Japan PMDA clinical consultation, while in Q1 2026 it reported PMDA was "inclined to accept this data" and FDA clarified it "view the appropriate approval pathway as a premarket approval" (CEO, President & Director Altman).
* The Helix device strategy became more specific: previously, Helix had a presubmission under review and an upcoming FDA feedback meeting; now BioCardia said FDA agreed there are "2 pathways" and "preferred" simultaneous approval with CardiAMP, while also suggesting a "de novo pathway as a stand-alone delivery system" via follow-on presubmission (CEO, President & Director Altman).
* Cash position declined from "$2.5 million" at year-end 2025 to "$951,000" at March 31, 2026 (Chief Financial Officer McClung), alongside Q2 2026 financing expectations stated by the CEO.

RISKS AND CONCERNS

* Funding and liquidity were an explicit operational focus given "cash and cash equivalents totaling $951,000" (Chief Financial Officer McClung) and the CEO’s plan that BioCardia "expect[s] to complete one or more transactions" to fund key programs (CEO, President & Director Altman).
* Execution risk was described in the Japan submission process, which the CEO characterized as "rather extensive" with audits across clinical and manufacturing threads (CEO, President & Director Altman).
* Trial execution and scaling were positioned as resource-dependent, with the CEO saying the company plans to expand enrollment sites "as fast as resources allow" (CEO, President & Director Altman).

FINAL TAKEAWAY

BioCardia’s management centered the quarter on regulatory momentum for CardiAMP in ischemic heart failure, saying Japan’s PMDA is inclined to accept the existing data as a basis for submission and describing an expected ~7-month preparation period followed by an approximately year-long review and post-marketing study with reimbursement. In the U.S., management said FDA discussions clarified a PMA pathway focus while encouraging completion of the ongoing CardiAMP HF II trial. With cash at $951,000 at quarter-end, management emphasized careful capital management and said it expects Q2 2026 transactions to fund both the Japan PMDA submission and the HF II trial, while outlining a Japan initial addressable use under appropriate-use conditions of about 20,000 patients and framing that scenario as a $400 million market using the company’s cited $20,000 U.S. reimbursement reference.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/bcda/earnings/transcripts]

MORE ON BIOCARDIA

* BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4905426-biocardia-inc-bcda-q1-2026-earnings-call-transcript]
* BioCardia, Inc. 2025 Q4 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4885578-biocardia-inc-2025-q4-results-earnings-call-presentation]
* BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4885576-biocardia-inc-bcda-q4-2025-earnings-call-transcript]
* BioCardia GAAP EPS of -$0.21 misses by $0.04 [https://seekingalpha.com/news/4593730-biocardia-gaap-eps-of--021-misses-by-004]
* BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit [https://seekingalpha.com/news/4568267-biocardia-outlines-imminent-cardiamp-fda-submission-and-targets-regulatory-catalysts-as-trial]